The mass tort market has fractured into two divergent realities in 2026: while the federal docket remains swollen with nearly 200,000 pending cases across 162 active MDLs, the flow of new litigation has collapsed. Filings dropped 50 percent year-over-year, from 75,570 in 2024 to 37,735 in 2025, signaling either market saturation or a fundamental shift in how plaintiffs and defendants approach mass exposure. Settlement dollars remain substantial—exceeding $40 billion annually for three consecutive years—but pricing for individual cases has fractured dramatically by category, geography, and stage of litigation. The Talc docket alone contains 68,400 pending cases, while emerging pharmaceuticals like Ozempic command per-case valuations an order of magnitude higher than mature torts.
What changed most is not the total size of the market, but its velocity and composition. The federal MDL system now operates at record capacity: 162 active dockets with 197,965 pending cases concentrated across 46 transferee districts, with the top 25 MDLs representing 95.2 percent of all pending mass tort litigation. Meanwhile, the cost to acquire a signed retainer has become a critical competitive factor, ranging from $500 to $800 per lead in emerging pharmaceutical cases to $5,000 to $6,000 in niche categories like baby formula necrotizing enterocolitis. Regional demand is no longer uniform—hotspots cluster around specific tort categories, and the market is pricing that concentration directly into lead acquisition and case management budgets.
Table of Contents
- Why the Federal MDL Docket Is at Maximum Capacity But New Filings Are Cratering
- Settlement Dollars Remain High, but Distribution Efficiency Tells a Grim Story
- Depo-Provera’s Explosive Growth and the Concentration of Demand
- Lead Acquisition Costs Mirror Litigation Demand—and Diverge Sharply by Category
- The Ozempic Mass Tort Signals Shifting Liability Expectations for Emerging Pharmaceuticals
- Why the 50 Percent Drop in New MDL Filings May Persist
- The Concentration of Settled Value in Three Legacy Categories
- Frequently Asked Questions
Why the Federal MDL Docket Is at Maximum Capacity But New Filings Are Cratering
The paradox is stark: the federal MDL system houses nearly 200,000 pending cases across 162 active dockets, yet new MDL filings collapsed by half in 2025. This suggests the system is not growing—it is consolidating. The top 25 MDLs represent 95.2 percent of all pending mass tort cases, meaning that concentration has intensified rather than dispersed. Long-dormant cases are being resolved, new wave litigation is slowing, and the middle tier of mass torts is disappearing. For practitioners, this means two things: cases sitting in mature dockets face longer resolution timelines because judges are managing record caseloads, and plaintiff’s lawyers who bet on new waves of litigation in untested categories face a market that may never materialize at scale.
The reasons for the filing decline are structural. Settlements in legacy torts like Roundup and talc have established damage caps and predictability, reducing incentive to file new MDLs. Regulatory agencies have become more proactive—the FDA moves faster on product recalls and warnings, narrowing the window for mass exposure to accumulate. And crucially, defendant-side litigation costs have risen sharply as class counsel become more selective about which cases to file. A pharmaceutical recall that might have generated 50,000 filings in 2015 now generates 2,800 to 3,191 filings distributed across MDL 3094 (Ozempic) and related dockets. The system is not dead; it is filtering.
Settlement Dollars Remain High, but Distribution Efficiency Tells a Grim Story
Three years of $40 billion annual settlements create an illusion of abundance. The reality is grimmer: for every dollar awarded in a class action or mass tort settlement, claimants receive only 53 cents. The remaining 47 cents—nearly half of the settlement value—is consumed by litigation costs, administrative expenses, case management, and attorney fees. In a $1 billion settlement, that leaves plaintiffs with roughly $530 million in direct payouts. Apply this ratio to the 3M Combat Arms Earplug settlement, which totaled $6.0 billion: as of July 1, 2026, approximately $3.03 billion has been distributed to claimants despite the participation rate exceeding 99 percent. The math is unforgiving.
This inefficiency is not random; it reflects the cost of managing mass litigation at scale. The 3M earplug settlement alone involved approximately 260,000 hearing loss claims and required a sophisticated claims administrator to verify eligibility, evaluate medical documentation, and process payments over years. Similar friction exists across all major dockets. The 3M PFAS settlement—tentatively valued at $10.3 billion to address contamination claims from public water systems—will face identical administrative and legal costs. For claimants in emerging cases like Ozempic, where legal analysts project total liability exceeding $2 billion and individual settlements ranging from $400,000 to $700,000 for severe gastroparesis cases (or over $1 million for vision loss claims), the distribution lag could stretch five to seven years. Early claimants who enroll in 2026 may not see payment until 2032.
Depo-Provera’s Explosive Growth and the Concentration of Demand
The most striking regional trend is not geographic—it is categorical. Depo-Provera, an injectable contraceptive, emerged as the fastest-growing mass tort in 2025 and 2026. The MDL contains 5,508 pending cases as of June 1, 2026, created in February 2025, representing 5,700 percent growth in a single year. For context: this is not incremental growth. This is a new exposure category that went from zero to near-blockbuster status in twelve months, driven by aggressive plaintiff marketing, growing medical awareness of side effects, and heightened social media amplification of injury narratives. The docket is still taking new filings and remains far from resolution.
Demand concentration is visible in three legacy categories as well. Talc litigation remains the single largest MDL with 68,400 pending cases, despite decades of litigation and multiple large settlements. AFFF firefighting foam claims grew 99 percent in 2025 alone, now comprising 15,213 pending cases. GLP-1 receptor agonist lawsuits (Ozempic, Mounjaro) grew 130 percent year-over-year and now represent 3,191 pending cases. These three categories—talc, AFFF, and GLP-1—represent roughly 40 percent of all pending mass tort cases and consume the vast majority of plaintiff-side resources, marketing budgets, and settlement negotiations. For law firms, this concentration means ruthless triage: betting on a fourth-tier tort category is now economically irrational.
Lead Acquisition Costs Mirror Litigation Demand—and Diverge Sharply by Category
The price tag to acquire a signed retainer in mass torts has become a leading indicator of market demand. The highest-cost leads are in niche, high-injury categories: Baby Formula necrotizing enterocolitis cases command $5,000 to $6,000 per signed retainer, reflecting both the severity of harm and the scarcity of eligible claimants. Mature torts like Roundup fall into a middle band: $2,800 to $3,500 per signed retainer. Emerging pharmaceuticals like GLP-1 receptor agonists are the cheapest on a per-retainer basis: $500 to $800 per signed retainer, driven by high case volume and low qualification barriers.
The general range across high-competition dockets (talc, AFFF) hovers between $1,500 and $4,000 per signed retainer. Digital advertising layer additional complexity. Facebook and Instagram cost $80 to $300 per qualified lead depending on tort category, geography, and audience saturation—but that is not the same as a signed retainer. The raw lead cost multiplier from qualified lead to signed retainer is 4 to 8 times, meaning a $100 Facebook lead in a hot tort (e.g., pharmaceutical recalls commanding $200 to $300 per qualified lead) ultimately costs $400 to $800 to convert into a signed retainer. Plaintiff’s firms trading on margin must navigate this funnel carefully: the cheapest leads are often in saturated markets where conversion rates are terrible, and the most expensive leads are in categories where case volume may not sustain the acquisition cost.
The Ozempic Mass Tort Signals Shifting Liability Expectations for Emerging Pharmaceuticals
The Ozempic litigation represents a new template for pharmaceutical mass torts. The MDL (No. 3094, Eastern District of Pennsylvania) contains 2,800 consolidated lawsuits against Novo Nordisk and Eli Lilly, with legal analysts projecting total liability exceeding $2 billion. Individual settlement ranges tell the story: $400,000 to $700,000 for severe gastroparesis cases, but over $1 million for vision loss (NAION) claims. First bellwether trials occurred in June 2026, providing early data on jury appetite for damages in pharmaceutical injury cases. This early trial data is critical because it signals whether jurors will award at the high or low end of projected ranges.
What distinguishes Ozempic from legacy torts is the speed of both the injury accumulation and the legal response. GLP-1 medications were approved in 2021 and 2022. Mass litigation began in earnest in 2023. By 2026—four years after approval—the system had consolidated 2,800 cases and held bellwether trials. Compare this to talc, which required decades to reach current volume, or Roundup, which faced similar acceleration but benefited from a single mega-settlement approach. The Ozempic pattern suggests pharmaceutical companies now face compressed litigation timelines. A product that injures thousands must assume MDL formation and rapid damage projections within 2–3 years of market awareness, not 10–20 years.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
Why the 50 Percent Drop in New MDL Filings May Persist
The collapse in new MDL filings is unlikely to reverse sharply. The reasons are economic and regulatory. First, defendants have learned to manage litigation risk more effectively through earlier warnings, restricted distribution, and aggressive settlement discussions before MDL formation. Second, the FDA and other regulatory bodies now intervene faster, either pulling products or issuing warnings that narrow the class of injured parties. Third, the attorneys who file MDLs face increasing scrutiny on conflict-of-interest grounds and must justify massive advertising spend and case acquisition costs before filing—a filter that did not exist in the 2015–2020 era.
A pharmaceutical manufacturer that might have faced 75,000 new filings a decade ago now faces 2,800 to 3,191 filings in the MDL-consolidated system. This shift has a practical consequence: the lawsuit lottery effect is diminishing. Plaintiff’s firms can no longer rely on a surprise explosion of new cases to offset acquisition costs. Instead, they must model each category carefully, project the settlement range, and decide whether the per-case profit supports the acquisition spend. For emerging torts like Depo-Provera (5,700 percent growth in one year), the market is still pricing cases aggressively. For mature torts like talc (68,400 cases over 25 years), pricing has stabilized and profit margins have compressed.
The Concentration of Settled Value in Three Legacy Categories
The $40 billion annual settlement figure masks a harsh truth: the vast majority of resolved dollars come from a small number of cases. The 3M Combat Arms Earplug settlement ($6.0 billion, with $3.03 billion already distributed as of July 2026) and the 3M PFAS settlement ($10.3 billion tentatively agreed in March 2024) represent roughly $16 billion in just two agreements. Add Roundup, talc, and AFFF settlements, and the majority of the $40 billion annual figure is accounted for. This concentration means that new plaintiff’s firms or smaller litigation shops struggle to compete for cases in mature torts where prices have stabilized and caseloads are known. The economics reward scale, aggregate volume, and access to capital to support long disputes.
For individual claimants, the practical message is sobering: the mass tort system delivers substantial total dollars, but the per-person payout depends entirely on category. A severe 3M earplug claimant might receive $5,000 to $25,000. An Ozempic vision loss claimant might receive $1 million or more. A Roundup lymphoma claimant faces a settlement pool that has already closed and residual claim values that have dropped to a fraction of early settlement amounts. The settlement dollar figure is real, but so is the arithmetic: $40 billion divided among 197,965 pending cases yields an average of roughly $202,000 per case—a figure that obscures the massive variance between blockbuster torts and category-specific closures.
Frequently Asked Questions
How long does it typically take to receive a payout from a mass tort settlement?
Most major settlements take 2–5 years from settlement agreement to distribution, depending on claims volume and administrative complexity. The 3M Combat Arms settlement, for example, began distributions in 2024 after the 2023 settlement agreement. Emerging litigation like Ozempic may face longer timelines—possibly 5–7 years from initial filing to full distribution.
Why are lead acquisition costs so different between Baby Formula and GLP-1 cases?
Baby Formula necrotizing enterocolitis cases involve rare, severe injuries with smaller eligible populations, making each claimant more valuable and harder to locate. GLP-1 cases involve more common side effects (gastroparesis, vision changes) with larger potential pools of injured parties, reducing the cost per qualified lead and per signed retainer.
Is the 50 percent drop in MDL filings permanent?
Likely yes, for structural reasons: faster FDA intervention, defendant litigation risk management, and plaintiff counsel filtering. However, emerging torts like Depo-Provera (which grew 5,700 percent in one year) show that new exposures can still generate rapid litigation. The pattern is selective, not zero.
What does “53 cents per dollar” mean for claimants?
For every $100 million in a settlement, claimants receive approximately $53 million in direct payouts. The remaining $47 million covers attorney fees, administrative costs, claims processing, and litigation expenses. This ratio applies broadly across mass torts and is one of the most criticized features of the system.
Which mass tort categories offer the highest individual settlement amounts?
Emerging pharmaceuticals (like Ozempic vision loss claims, projected over $1 million) and niche severe injury categories (like Baby Formula NEC) command the highest per-case valuations. Mature torts like talc and Roundup have lower per-case payouts as settlement pools close and residual claims decline in value.
How do I know if my case fits into an active MDL?
The federal judiciary maintains a public list of all active MDLs, searchable by product, date of transfer, and transferee judge. If your injury stems from a recalled product, medication, or mass exposure (environmental, occupational, medical device), check the MDL tracker to see if litigation is consolidated or still individual filings.
You Might Also Like
- Mass Tort New 72-Hour Update: Eligibility Dates and Practical Next Steps
- Mass Tort Tips and Strategies
- Mass Tort State-by-State Guide: Rules Deadlines and Local Impact Explained